JOP20160150B1 - Substituted quinazoline compounds and methods of use thereof - Google Patents
Substituted quinazoline compounds and methods of use thereofInfo
- Publication number
- JOP20160150B1 JOP20160150B1 JOP/2016/0150A JOP20160150A JOP20160150B1 JO P20160150 B1 JOP20160150 B1 JO P20160150B1 JO P20160150 A JOP20160150 A JO P20160150A JO P20160150 B1 JOP20160150 B1 JO P20160150B1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- compounds
- quinazoline compounds
- substituted quinazoline
- activity
- Prior art date
Links
Abstract
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018502355A JP6869947B2 (en) | 2015-07-22 | 2016-07-22 | Use of substituted quinazoline compound and its G12C mutant KRAS, HRAS and / or NRAS protein as an inhibitor |
MX2018000777A MX2018000777A (en) | 2015-07-22 | 2016-07-22 | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins. |
CA2993013A CA2993013A1 (en) | 2015-07-22 | 2016-07-22 | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
EP16747678.7A EP3325447A1 (en) | 2015-07-22 | 2016-07-22 | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
TW105123325A TW201713630A (en) | 2015-07-22 | 2016-07-22 | Substituted quinazoline compounds and methods of use thereof |
CN201680053297.5A CN108026046B (en) | 2015-07-22 | 2016-07-22 | Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and/or NRAS proteins |
PCT/US2016/043568 WO2017015562A1 (en) | 2015-07-22 | 2016-07-22 | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
HK18111923A HK1252622A1 (en) | 2015-07-22 | 2018-09-17 | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195636P | 2015-07-22 | 2015-07-22 | |
US201662342078P | 2016-05-26 | 2016-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20160150B1 true JOP20160150B1 (en) | 2021-08-17 |
Family
ID=60244722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2016/0150A JOP20160150B1 (en) | 2015-07-22 | 2016-07-21 | Substituted quinazoline compounds and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR105458A1 (en) |
JO (1) | JOP20160150B1 (en) |
-
2016
- 2016-07-21 JO JOP/2016/0150A patent/JOP20160150B1/en active
- 2016-07-22 AR ARP160102249A patent/AR105458A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR105458A1 (en) | 2017-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018000777A (en) | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins. | |
EA033689B9 (en) | Inhibitors of kras g12c | |
PH12019550248A1 (en) | Covalent inhibitors of kras | |
WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
EA201891191A1 (en) | 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION | |
MX2021005924A (en) | Compounds and methods of use thereof for treatment of cancer. | |
MX2021000887A (en) | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer. | |
MX2017013275A (en) | Fused-tricyclic inhibitors of kras and methods of use thereof. | |
JO3805B1 (en) | Inhibitors of kras g12c | |
PH12017500367B1 (en) | Compounds that inhibit mcl-1 protein | |
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
MX2019009501A (en) | Amino pyrimidine compounds useful as ssao inhibitors. | |
MX2021010297A (en) | Human plasma kallikrein inhibitors. | |
MX2018011592A (en) | Compound having mutant idh inhibitory activity, preparation method and use thereof. | |
PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
MX2018007511A (en) | Alkynyl dihydroquinoline sulfonamide compounds. | |
TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
MX2017014301A (en) | Compositions and methods for the treatment or prevention of pulmonary hypertension. | |
JOP20160150B1 (en) | Substituted quinazoline compounds and methods of use thereof | |
WO2018067638A3 (en) | High mobility group b1 protein inhibitors | |
MX2019014773A (en) | Ccl2 inhibitors. | |
MY188058A (en) | Inhibitors of kras g12c | |
EA202091668A3 (en) | HUMAN PLASMA CALLICREIN INHIBITORS |